{"id":9538,"date":"2026-02-24T23:28:30","date_gmt":"2026-02-24T15:28:30","guid":{"rendered":"https:\/\/regask.com\/?p=9538"},"modified":"2026-02-24T23:28:30","modified_gmt":"2026-02-24T15:28:30","slug":"lagence-nationale-de-reglementation-des-medicaments-de-bahrein-nhra-publie-une-version-actualisee-de-ses-lignes-directrices-sur-les-variations-de-medicaments-a-usage-humain-version-3-2","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/","title":{"rendered":"L\u2019autorit\u00e9 NHRA de Bahre\u00efn publie une version actualis\u00e9e de ses directives sur les variations de m\u00e9dicaments\u2026"},"content":{"rendered":"<p>Sur <strong>21 janvier 2026,<\/strong> le <strong>Autorit\u00e9 nationale de r\u00e9glementation sanitaire (NHRA)<\/strong> a publi\u00e9 une mise \u00e0 jour <strong>Lignes directrices relatives aux variations des m\u00e9dicaments \u00e0 usage humain.<\/strong> La directive, <strong>Version 3.2 (janvier 2026),<\/strong> s&#039;applique \u00e0 <strong>m\u00e9dicaments \u00e0 usage humain b\u00e9n\u00e9ficiant d&#039;une autorisation de mise sur le march\u00e9 valide de la NHRA<\/strong> et d\u00e9finit les exigences r\u00e9glementaires en mati\u00e8re de gestion<strong> variations apr\u00e8s approbation,<\/strong> y compris la classification, les voies de soumission, la documentation, les d\u00e9lais d&#039;\u00e9valuation et les attentes en mati\u00e8re de mise en \u0153uvre.<\/p>\n<div class=\"row\"  id=\"row-2120575205\">\n\n\t<div id=\"col-765465363\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-1570360349\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1570360349 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>D\u00e9tails de la mise \u00e0 jour<\/h2>\n\t<div id=\"gap-2112378752\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2112378752 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>La directive mise \u00e0 jour s&#039;applique \u00e0 <strong>modifications apport\u00e9es aux m\u00e9dicaments \u00e0 usage humain<\/strong> qui d\u00e9tiennent d\u00e9j\u00e0 une autorisation de commercialisation de la NHRA et une licence valide. Il explique comment les variations post\u00e9rieures \u00e0 l&#039;approbation sont class\u00e9es en <strong>Type IA, Type IB, <\/strong>et<strong> Type II,<\/strong> distinguer les changements mineurs de ceux qui peuvent avoir une incidence significative <strong>qualit\u00e9, s\u00e9curit\u00e9 ou efficacit\u00e9.\u00a0<\/strong><\/p>\n<p>La directive pr\u00e9cise que <strong>Variantes de type IA<\/strong> suivre une approche \u201c\u00a0faire et expliquer\u00a0\u201d, permettant la mise en \u0153uvre sans approbation pr\u00e9alable mais exigeant <strong>notification dans un d\u00e9lai de 60 jours ouvrables<\/strong> apr\u00e8s mise en \u0153uvre, avec possibilit\u00e9 de rejet si les conditions ne sont pas remplies. <strong>Variantes de type IB<\/strong> sont g\u00e9r\u00e9es selon un processus \u201c\u00a0Dire, Attendre et Agir\u00a0\u201d, tandis que <strong>variantes de type II<\/strong> couvrir les changements majeurs n\u00e9cessitant une \u00e9valuation compl\u00e8te avant leur mise en \u0153uvre.<\/p>\n<p>Toutes les demandes de modification doivent \u00eatre soumises via le <strong>Syst\u00e8me en ligne NHRA Adweya,<\/strong> en utilisant <strong>Document technique commun \u00e9lectronique (eCTD)<\/strong> s\u00e9quences. Le guide pr\u00e9cise les attentes en mati\u00e8re de documentation, notamment <strong>lettres de motivation, comparaisons entre l&#039;\u00e9tat actuel et l&#039;\u00e9tat propos\u00e9,<\/strong> et <strong>approbations ou preuves du pays d&#039;origine,<\/strong> le cas \u00e9ch\u00e9ant.<\/p>\n<p>En ce qui concerne les d\u00e9lais r\u00e9glementaires, la NHRA indique des p\u00e9riodes d&#039;ach\u00e8vement d&#039;\u00e9valuation pr\u00e9vues de <strong>7 jours ouvrables pour le type IA<\/strong> variations et <strong>40 jours ouvrables pour les types IB et II<\/strong> variations. Pour les modifications approuv\u00e9es, la directive pr\u00e9cise que <strong>Les variantes de type IB et de type II devraient \u00eatre mises en \u0153uvre dans un d\u00e9lai de 12 mois.<\/strong> \u00e0 compter de la date de la lettre d&#039;approbation.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-765465363 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-2086755898\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Date d&#039;entr\u00e9e en vigueur<\/h2>\n\t<div id=\"gap-1569488439\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1569488439 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Le <strong>La directive sur les variations de m\u00e9dicaments (version 3.2) est applicable \u00e0 compter du 21 janvier 2026. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2086755898 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1482404589\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Pourquoi c&#039;est important<\/h2>\n\t<div id=\"gap-1694034089\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1694034089 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Cette mise \u00e0 jour harmonise davantage la r\u00e9glementation relative \u00e0 la classification, la soumission, l&#039;examen et la mise en \u0153uvre des modifications apport\u00e9es aux m\u00e9dicaments \u00e0 usage humain apr\u00e8s leur autorisation de mise sur le march\u00e9 au Bahre\u00efn. <strong>exigences de soumission num\u00e9rique, \u00e9ch\u00e9anciers normalis\u00e9s et fen\u00eatres de mise en \u0153uvre,<\/strong> Cette directive favorise un traitement r\u00e9glementaire plus efficace tout en maintenant les contr\u00f4les de conformit\u00e9 et en minimisant l&#039;incertitude administrative pour les titulaires d&#039;autorisation de mise sur le march\u00e9.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1482404589 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1734260591\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>\u00c0 qui cela s&#039;adresse-t-il ?<\/h2>\n\t<div id=\"gap-1486136716\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1486136716 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Cette mise \u00e0 jour est pertinente pour <strong>\u00c9quipes des affaires r\u00e9glementaires, de l&#039;assurance qualit\u00e9, de la conformit\u00e9, de la CMC et des op\u00e9rations informatiques ou r\u00e9glementaires<\/strong> responsable de la gestion des modifications post-approbation et des soumissions \u00e9lectroniques pour les m\u00e9dicaments \u00e0 usage humain autoris\u00e9s \u00e0 Bahre\u00efn.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1734260591 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1639006522\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Prochaines \u00e9tapes<\/h2>\n\t<div id=\"gap-1046917699\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1046917699 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Les entreprises devraient revoir leur <strong>proc\u00e9dures de gestion des variations<\/strong> afin de garantir la conformit\u00e9 avec les exigences mises \u00e0 jour de la NHRA. Cela comprend la v\u00e9rification de la conformit\u00e9 <strong>classification des variations,<\/strong> r\u00e9union <strong>D\u00e9lais de notification de type IA,<\/strong> se pr\u00e9parer <strong>soumissions conformes \u00e0 la norme eCTD<\/strong> via le syst\u00e8me Adweya, et en ajustant les flux de travail internes pour r\u00e9pondre aux exigences d\u00e9clar\u00e9es <strong>Calendrier d&#039;\u00e9valuation et de mise en \u0153uvre. <\/strong><\/p>\n<p><span class=\"TextRun SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\">\u00c0 mesure que les organisations s&#039;adaptent \u00e0 ces nouvelles exigences de post-approbation,\u00a0<\/span><\/span><a href=\"http:\/\/regask.com\/fr\/\"><strong><span class=\"TextRun MacChromeBold SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW200731050 BCX0\">RegASK<\/span><\/span><\/strong><\/a><span class=\"TextRun SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\">\u00a0peut permettre une gestion de la conformit\u00e9 plus structur\u00e9e et proactive.\u00a0<\/span><a href=\"http:\/\/regask.com\/fr\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW200731050 BCX0\">RegASK<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW200731050 BCX0\"> est une plateforme de pointe d&#039;intelligence r\u00e9glementaire et d&#039;orchestration des flux de travail bas\u00e9e sur l&#039;IA agentielle, qui permet aux organisations mondiales des secteurs hautement r\u00e9glement\u00e9s, notamment les produits de consommation et les sciences de la vie, de naviguer de mani\u00e8re proactive dans des environnements r\u00e9glementaires complexes. <strong>En combinant une IA agentique avanc\u00e9e avec des experts impliqu\u00e9s, <\/strong><\/span><a href=\"http:\/\/regask.com\/fr\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW200731050 BCX0\">RegASK<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW200731050 BCX0\">\u00a0livre\u00a0<\/span><span class=\"NormalTextRun SCXW200731050 BCX0\">opportun<\/span><span class=\"NormalTextRun SCXW200731050 BCX0\"> Des analyses pr\u00e9dictives exploitables et une automatisation de bout en bout, rationalisant les processus de conformit\u00e9, att\u00e9nuant les risques et acc\u00e9l\u00e9rant l&#039;acc\u00e8s au march\u00e9 dans plus de 160 pays. <\/span><\/span><a href=\"http:\/\/regask.com\/fr\/\"><strong><span class=\"TextRun MacChromeBold SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\">En savoir plus <\/span><\/span><\/strong><\/a><span class=\"TextRun MacChromeBold SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\">ou<\/span><\/span><a href=\"https:\/\/regask.com\/fr\/reserver-une-demo\/\"><strong><span class=\"TextRun MacChromeBold SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\"> r\u00e9servez une d\u00e9mo maintenant.<\/span><\/span><\/strong><\/a><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1639006522 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-68926099\">\n\n\t<div id=\"col-853677331\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQ<\/h3>\n\t<div id=\"gap-341324399\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-341324399 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4>Quelles sont les directives de la NHRA de Bahre\u00efn concernant les variations de m\u00e9dicaments\u00a0?<\/h4>\n\t<div id=\"gap-806406715\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-806406715 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Il s&#039;agit d&#039;une directive officielle \u00e9mise par la NHRA de Bahre\u00efn qui d\u00e9finit comment les modifications apport\u00e9es apr\u00e8s l&#039;approbation aux m\u00e9dicaments \u00e0 usage humain autoris\u00e9s doivent \u00eatre class\u00e9es, soumises, examin\u00e9es et mises en \u0153uvre.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-853677331 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-379548423\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Quels types de variations sont couverts par cette directive\u00a0?<\/h4>\n\t<div id=\"gap-1685359692\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1685359692 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Les lignes directrices couvrent <strong>Type IA, Type IB, <\/strong>et<strong> Type II<\/strong> des variations, allant de modifications mineures \u00e0 des modifications majeures susceptibles d&#039;avoir un impact sur la qualit\u00e9, la s\u00e9curit\u00e9 ou l&#039;efficacit\u00e9.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-379548423 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1999430936\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Comment les demandes de modification doivent-elles \u00eatre soumises \u00e0 la NHRA\u00a0?<\/h4>\n\t<div id=\"gap-1953081820\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1953081820 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Toutes les demandes de modification doivent \u00eatre soumises via le <strong>Syst\u00e8me en ligne NHRA Adweya utilisant des s\u00e9quences eCTD,<\/strong> ainsi que les documents justificatifs requis.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1999430936 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-809389784\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Comment la norme RegASK peut-elle aider les entreprises \u00e0 g\u00e9rer les variations post\u00e9rieures \u00e0 l&#039;approbation de la NHRA\u00a0?<\/h4>\n\t<div id=\"gap-515225044\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-515225044 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong><a href=\"http:\/\/regask.com\/fr\/\">RegASK<\/a><\/strong> aide les \u00e9quipes \u00e0 suivre les mises \u00e0 jour r\u00e9glementaires, \u00e0 aligner les flux de travail internes sur les exigences de variation et \u00e0 g\u00e9rer la soumission des documents de pr\u00e9paration gr\u00e2ce \u00e0 une intelligence r\u00e9glementaire pilot\u00e9e par l&#039;IA et \u00e0 une orchestration de la conformit\u00e9.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-809389784 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>On January 21, 2026, the National Health Regulatory Authority (NHRA) published an updated Medicine Variations Guideline for Human Medicines. The guideline, Version 3.2 (January 2026), applies to human medicines with a valid NHRA marketing authorization and sets out the regulatory requirements for managing post-approval variations, including classification, submission pathways, documentation, assessment timelines, and implementation expectations.<\/p>","protected":false},"author":43,"featured_media":9539,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,533,35],"tags":[],"class_list":["post-9538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-middle-east","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.8 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bahrain NHRA Publishes Updated Medicine Variations<\/title>\n<meta name=\"description\" content=\"Bahrain NHRA publishes updated Medicine Variations Guideline for Human Medicines, Version 3.2, outlining key regulatory changes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/lagence-nationale-de-reglementation-des-medicaments-de-bahrein-nhra-publie-une-version-actualisee-de-ses-lignes-directrices-sur-les-variations-de-medicaments-a-usage-humain-version-3-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bahrain NHRA Publishes Updated Medicine Variations Guideline for Human Medicines (Version 3.2)\" \/>\n<meta property=\"og:description\" content=\"Bahrain NHRA publishes updated Medicine Variations Guideline for Human Medicines, Version 3.2, outlining key regulatory changes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/lagence-nationale-de-reglementation-des-medicaments-de-bahrein-nhra-publie-une-version-actualisee-de-ses-lignes-directrices-sur-les-variations-de-medicaments-a-usage-humain-version-3-2\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T15:28:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"Bahrain NHRA Publishes Updated Medicine Variations Guid&hellip;\",\"datePublished\":\"2026-02-24T15:28:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\"},\"wordCount\":806,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\",\"articleSection\":[\"Regulatory News\",\"Middle East\",\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\",\"name\":\"Bahrain NHRA Publishes Updated Medicine Variations\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\",\"datePublished\":\"2026-02-24T15:28:30+00:00\",\"description\":\"Bahrain NHRA publishes updated Medicine Variations Guideline for Human Medicines, Version 3.2, outlining key regulatory changes.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\",\"width\":800,\"height\":600,\"caption\":\"Bahrain Nhra Publishes Updated Medicine Variations Guideline Human Medicines Version 3 2\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"L&#039;autorit\u00e9 NHRA de Bahre\u00efn publie une mise \u00e0 jour des variations de m\u00e9dicaments","description":"L&#039;agence nationale de r\u00e9glementation des m\u00e9dicaments de Bahre\u00efn (NHRA) publie une version mise \u00e0 jour de ses lignes directrices sur les variations de m\u00e9dicaments pour les m\u00e9dicaments \u00e0 usage humain, version 3.2, qui d\u00e9crit les principaux changements r\u00e9glementaires.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/lagence-nationale-de-reglementation-des-medicaments-de-bahrein-nhra-publie-une-version-actualisee-de-ses-lignes-directrices-sur-les-variations-de-medicaments-a-usage-humain-version-3-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Bahrain NHRA Publishes Updated Medicine Variations Guideline for Human Medicines (Version 3.2)","og_description":"Bahrain NHRA publishes updated Medicine Variations Guideline for Human Medicines, Version 3.2, outlining key regulatory changes.","og_url":"https:\/\/regask.com\/fr\/lagence-nationale-de-reglementation-des-medicaments-de-bahrein-nhra-publie-une-version-actualisee-de-ses-lignes-directrices-sur-les-variations-de-medicaments-a-usage-humain-version-3-2\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-02-24T15:28:30+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#article","isPartOf":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"Bahrain NHRA Publishes Updated Medicine Variations Guid&hellip;","datePublished":"2026-02-24T15:28:30+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/"},"wordCount":806,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","articleSection":["Regulatory News","Middle East","Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/","url":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/","name":"L&#039;autorit\u00e9 NHRA de Bahre\u00efn publie une mise \u00e0 jour des variations de m\u00e9dicaments","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","datePublished":"2026-02-24T15:28:30+00:00","description":"L&#039;agence nationale de r\u00e9glementation des m\u00e9dicaments de Bahre\u00efn (NHRA) publie une version mise \u00e0 jour de ses lignes directrices sur les variations de m\u00e9dicaments pour les m\u00e9dicaments \u00e0 usage humain, version 3.2, qui d\u00e9crit les principaux changements r\u00e9glementaires.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","width":800,"height":600,"caption":"Bahrain Nhra Publishes Updated Medicine Variations Guideline Human Medicines Version 3 2"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/9538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=9538"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/9538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/9539"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=9538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=9538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=9538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}